Canadian Task Force on Preventive Health Care

Selected References

Preventive Health Care, 2000 Update: Screening and Management of Hyperhomocysteinemia for the Prevention of Coronary Artery Disease Events

Prepared by Gillian L. Booth, MD, Departments of Medicine, Clinical Epidemiology and Health Care Research Program, University of Toronto, Elaine E. L. Wang, MD, Departments of Pediatrics, Clinical Epidemiology and Health Care Research Program, University of Toronto

These recommendations were finalized by the Task Force in July 1999

  1. Statistics Canada. Causes of death, 1995 (Catalogue 84-208-XPB). 1997. Ottawa, Minister of Industry.
  2. Brophy JM. The epidemiology of acute myocardial infarction and ischemic heart disease in Canada. data from 1976 to 1991. Can J Cardiol 1997;13:474-478.
  3. Skovby F. Inborn errors of metabolism causing homocysteinemia and related vascular involvement.  Haemostasis 1989;19(suppl 1):4-9.
  4. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Gröbe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathione-synthase deficiency. Am J Hum Genet 1985;37:1-31.
  5. Moghadasian MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 1997;157:2299-2308.
  6. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-527.
  7. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Medicine 1998;49:31-62.
  8. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998;158:2101-2106.
  9. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-1835.
  10. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
  11. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.  JAMA 1995;274:1049-1057.
  12. Woolf SH, Battista RN, Anderson GM, Logan AG, Wang E, and the Canadian Task Force on the Periodic Health Examination. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epidemiol 1990;43:891-905.
  13. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993;39:1964-1979.
  14. Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol 1996;77:759-764.
  15. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998;44:311-316.
  16. Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994;60:2-11.
  17. Olszewski AJ, Szostak WB. Homocysteine content of plasma proteins in ischemic heart disease.  Atherosclerosis 1988;69:109-113.
  18. Genest JJJ, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16:1114-1119.
  19. Kang SS, Wong PWK, Susman A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydro- folate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991;48:536-545.
  20. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kottke-Marchant K, Savon SR, Selhub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92:2825-2830.
  21. Aronow WS, Ahn C. Association between plasma homocysteine and coronary artery disease in older persons. Am J Cardiol 1997;80:1216-1218.
  22. Verhoef P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler SP, Reynolds RD, Kok FJ, Hennekens CH, Willett WC. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 1996;143:845-859.
  23. Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzgang CR, Anderson PH, Seltzer D, Upson B, Lin QR. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997;17:1157-1162.
  24. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, Genest J Jr, Rozen R.  Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1997;17:569-573.
  25. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly K, Hess DL, Psaty BM, Longstreth WT Jr, Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997;96:412-417.
  26. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR, Hopkins PN. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem 1994;40:552-561.
  27. Malinow MR, Ducimetiere P, Luc G, Evans AE, Arveiler D, Cambien F, Upson BM. Plasma homocyst(e)ine levels and graded risk for myocardial infarction: findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996;126:27-34.
  28. Loehrer FMT, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler B. Low whole-blood S-adenosyl-methionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol 1996;17:1157-1162.
  29. Kang SS, Wong PWK, Cook HY, Norusis M, Messer JV. Protein-bound homocyst(e)ine.  A possible risk factor for coronary artery disease. J Clin Invest 1986;77:1482-1486.
  30. Ubbink JB, Vermaak WHJ, Bennett JM, Becker S, van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease.  Klin Wochenschr 1991;69:527-534.
  31. von Eckardstein A, Malinow MR, Upson B, Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994;14:460-464.
  32. Montalescot G, Ankri A, Chadefaux-Vekemans B, Blacher J, Philippe F, Drobinski G, Benzidia R, Kamoun P, Thomas D. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Atherosclerosis 1997;126:27-34.
  33. Dalery K, Lussier-Cacan S, Selhub J, Davignon J, Latour Y, Genest JJJ. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol 1995;75:1107-1111.
  34. Panicharuniti N, lewis CA, Sauberlich HE, Perkins LL, Go RCP, Alvarez JO, Macaluso M, Acton RT, Copeland RB, Cousins AL, Gore TB, Cornwell PE, Roseman JM. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994;59:940-948.
  35. Graham IM, Daly LE, Refsum H, Robinson K, Brattström LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Roulaud FM, Tan KS, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-1781.
  36. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.
  37. Lolin YI, Sanderson JE, Cheng SK, Chan CF, Pang CP, Woo KS, Masarei JRL. Hyperhomocysteinaemia and premature coronary artery disease in the Chinese.  Heart 1996;76:117-122.
  38. Verhoef P, Kok FJ, Kruyssen DACM, Schouten EG, Witteman JCM, Grobbee DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:989-995.
  39. Israelsson B, Brattström LE, Hultberg BL: Homocysteine and myocardial infarction. Atherosclerosis 1988;71:227-233.
  40. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease.  N Engl J Med 1991; 324:1149-1155.
  41. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976;57:1079-1082.
  42. Murphy-Chutorian DR, Wexman MP, Grieco AJ, Heininger JA, Glassman E, Gaull GE, Ng SKC, Feit F, Wexman K, Fox AC. Methionine intolerance: a possible risk factor for coronary artery disease. J Am Coll Cardiol 1985;6:725-730.
  43. Donner MG, Klein GK, Mathes PB, Schwandt P, Richter WO. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile. Metabolism: Clin & Exper 1998;47:273-279.
  44. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 1983;32:363-370.
  45. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylene-tetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation 1996; 94:1812-1814.
  46. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-867.
  47. Nygård O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998;67:263-270.
  48. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJC, Jakobs C, Bouter LM, Heine RJ, Stehouwer CDA. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998;158:862-867.
  49. Stampfer MJ, Malinow MR, Willet WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
  50. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-709.
  51. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JCM, Koudstaal PJ, Grobbee DE. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly. The Rotterdam Study. Arch Intern Med 1999;159:38-44.
  52. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998;98:204-210.
  53. Evans RW, Shaten J, Hempel JD, Cutler JA, Kuller LH, for the MRFIT Research Group: Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial.  Arterioscler Thromb Vasc Biol 1997;17:1947-1953.
  54. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994;106:9-19.
  55. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willet WC, Stampfer MJ. Plasma total  homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997;79:799-801.
  56. Ubbink JB, Fehily AM, Pickering J, Elwood PC, Vermaak WJH. Homocysteine and ischaemic heart disease in the Caerphilly cohort. Atherosclerosis 1998;140:349-356.
  57. Stehouwer CDA, Weijenberg MP, van den Berg M, Jakobs C, Feskens EJM, Kromhout D. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol 1998;18:1895-1901.
  58. Bostom A, Silbershatz H, Rosenberg IH, Selhub J, D’Agostino RB, Wolf PA, Jacques PF, Wilson PWF. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077-1080.
  59. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.
  60. Taylor LMJ, Moneta GL, Sexton GJ, Schuff RA, Porter JM, and The Homocysteine and Progression of Atherosclerosis Study Investigators. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surgery 1999;29:8-21.
  61. Eritsland J, Arnesen H, Seljeflot I, Abdelnoor M, Grønseth K, Berg K, Malinow MR. Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting. Am J Cardiol 1994;74:1099-1102.
  62. Verhoef P, Kok FJ, Kluijtmans LAJ, Blom HJ, Refsum H, Ueland PM. The 677CT mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997;132:105-113.
  63. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, Faccini G, Pignatti PF, Mazzucco A, Corrocher R. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998; 91:4158-4163.
  64. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJP, Reitsma PH. The effect of a common methylene-tetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis 1998;141:161-166.
  65. Thuillier L, Chadefaux-Vekemans B, Bonnefont JP, Kara A, Aupetit J, Rochette C, Montalescot G, Couty MC, Kamoun P, Ankri A. Does the polymorphism 677C-T of the 5,10-methylenetetrahydro- folate reductase gene contribute to homocysteine-related vascular disease? J Inher Metab Dis 1998; 21:812-822.
  66. Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, Jukema JW, van den Heuvel LPWJ, Trijbels FJM, Boerma GJM, Verheugt FWA, Willems F, Blom HJ. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1997;96:2573-2577.
  67. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997;95:2032-2036.
  68. Ou T, Yamakawa-Kobayashi K, Arinami T, Amemiya H, Fujiwara H, Kawata K, Saito M, Kikuchi S, Noguchi Y, Sugishita Y, Hamaguchi H. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998;137:23-28.
  69. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M: Molecular variant of 5,10-methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis 1996;121:293-294.
  70. Morita H, Kurihara H, Sugiyama T, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y. Polymorphism of the methionine synthase gene. Association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol 1999;19:298-302.
  71. Wilcken DEL, Wang XL, Sim AS, McCredie RM. Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677 T mutation. Arterioscler Thromb Vasc Biol 1996;16:878-882
  72. Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis 1997;128:107-112.
  73. van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997;95:21-23.
  74. Anderson JL, King GJ, Thomson MJ, Todd M, Bair TL, Muhlestein JB, Carlquist JF. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol 1997;30:1206-1211.
  75. Brattström LE, Wilcken DEL, Öhrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of a meta-analysis. Circulation 1998;98:2520-2526.
  76. Matsushita S, Muramatsu T, Arai H, Matsui T, Higuchi S. The frequency of the methylenetetra-hydrofolate reductase-gene mutation varies with age in the normal population. Am J Hum Genet 1997;61:1459-1460.
  77. Brattström LE, Zhang Y, Hurtig M, Refsum H, Östensson S, Fransson L, Jonés K, Landgren F, Brudin L Ueland PM. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis 1998;141:315-319.
  78. Refsum H, Ueland PM. Recent data are not in conflict with homocysteine as a cardiovascular risk factor. Curr Opin Lipidol 1998;9:533-539.
  79. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996;275:1893-1896.
  80. Chason-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler PV, Willett W, Hennekens CH, Stampfer MJ. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1999;15:136-143.
  81. Robinson K, Arheart K, Refsum H, Brattström L, Boers G, Ueland P, Rubba P, Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I, for the European COMAC group. Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998;97:437-443.
  82. den Heijer M, Brouwer IA, Bos GMJ, Blom HJ, van der Put NMJ, Spaans AP, Rosendaal FR, Thomas CMG, Haak HL, Wijermans PW, Gerrits WBJ. Vitamin supplementation reduces blood homocysteine levels. A controlled trial in patients with venous thrombosis and healthy volunteers.  Arterioscler Thromb Vasc Biol 1998;18:356-361.
  83. Woodside JV, Yarnell JWG, McMaster D, Young IS, Harmon DL, McCrum EE, Patterson CC, Gey KF, Whitehead AS, Evans A. Effect of B-group vitamins and antioxidant vitamins on hyperhomo-cysteinemia: a double-blind, randomized, factorial-design, controlled trial. Am J Clin Nutr 1998; 67:858-866.
  84. Naurath HJ, Joosten E, Riezler R, Stabler SP, Allen RH, Lindenbaum J. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations.  Lancet 1995;346:85-89.
  85. Ubbink JB, van der Merwe A, Vermaak WHJ, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Invest 1993;71:993-998.
  86. Ubbink JB, Vermaak WHJ, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927-1933.
  87. Dierkes J, Kroesen M, Pietrzik K. Folic acid and vitamin B6 supplementation and plasma homocysteine concentrations in healthy young women. Int J Vit Nutr Res 1998;68:98-103.
  88. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998;316:894-898.
  89. Guttormsen AB, Ueland PM, Nesthus I, Nygård O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (40 mol/liter). The Hordaland Homocysteine Study. J Clin Invest 1996;98:2174-2183.
  90. Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG, Scott JM. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. Q J Med 1997;90:519-524.
  91. Jacob RA, Wu MM, Henning SM, Swendseid ME. Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J Nutr 1994;124:1072-1080.
  92. van den Berg M, Franken DG, Boers GHJ, Blom HJ, Jakobs C, Stehouwer CDA, Rauwerda JA.  Combined vitamin B6 plus folic acid therapy in young patients with arteriosclerosis and hyper-homocysteinemia. J Vasc Surgery 1994;20:933-940.
  93. Dudman NPB, Wilcken DEL, Wang J, Lynch JF, Macey D, Lundberg P. Disordered methionine/ homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb 1993;13:1253-1260.
  94. Brattström LE, Israelsson B, Norrving B, Bergqvist D, Thorne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60.
  95. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM. Effect of various regimens of vitamin B6 and folic acid on mild hyperhomocysteinaemia in vascular patients. J Inher Metab Dis 1994;17:159-162.
  96. Franken DG, Boers GHJ, Blom HJ, Trijbels FJM, Kloppenborg PWC. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994;14:465-470.
  97. Cuskelly GJ, McNulty H, McPartlin JM, Strain JJ, Scott JM. Plasma homocysteine response to folate intervention in young women. Ir J Med Sci 1995;164:3
  98. Schorah CJ, Devitt H, Lucock M, Dowell AC. The responsiveness of plasma homocysteine to small increases in dietary folic acid: a primary care study. Eur J Clin Nutr 1998;52:407-411.
  99. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-1454.
  100. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PC, Upson BM. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-1015.
  101. Rimm EB, Willet WC, Hu FB, Sampson L, Colditz GA, Manson JE, Hennekens C, Stampfer MJ.  Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359-364.
  102. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia.  Lancet 1998;351:
  103. Wilcken DEL, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inher Metab Dis 1997;20:295-300.
  104. Tucker KL, Mahnken B, Wilson PWF, Jacques P, Selhub J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA 1996;276:1879-1885.
  105. Malinow MR, Bostom A, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases. A statement for healthcare professionals from the nutrition committee, American Heart Association.  Circulation 1999;99:178-182.
  106. Omenn GS, Beresford SAA, Motulsky AG. Preventing coronary heart disease: B vitamins and homocysteine. Circulation 1998;97:421-424.
  107. Genest JJJ. Hyperhomocyst(e)inemia – determining factors and treatment. Can J Cardiol 1999; 15(suppl B):35B-38B.
  108. Eikelboom JW, Lonn E, Genest JJ, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-375.

Link to Full Text of this review

Link to Structured Abstract of this review

Link to Summary Table of Recommendations of this review

Top of Page

Home PageCTFPHC Home Page

Reprinted in modified format by the Canadian Task Force on Preventive Health Care
Original Copyright © 2000 Canadian Medical Association.
For any technical issues please contact: webmaster@ctfphc.org
Last modified: July 13, 2000.